Hematology, Transfusion and Cell Therapy最新文献

{"title":"Coagulation factor stability and sterility of thawed fresh frozen plasma stored at 2-6 o C for five days: Towards optimizing utilization","authors":"Ruchika Bhartia,&nbsp;Paramjit Kaur,&nbsp;Kshitija Mittal,&nbsp;Anita Tahlan,&nbsp;Varsha Gupta,&nbsp;Ravneet Kaur,&nbsp;Gagandeep Kaur","doi":"10.1016/j.htct.2025.103988","DOIUrl":"10.1016/j.htct.2025.103988","url":null,"abstract":"<div><h3>Background</h3><div>Fresh frozen plasma plays a crucial role in managing trauma and bleeding patients. The concern about a decline in labile coagulation factors limits its usage beyond 24 hours. This study aimed to analyze coagulation factor levels and microbial contamination of thawed fresh frozen plasma stored at 2-6 °C for five days.</div></div><div><h3>Material and methods</h3><div>A prospective observational study was conducted on 40 male donors with blood groups A and O selected through purposive sampling. Blood was collected in 450 mL bags and freshly prepared plasma was aliquoted and frozen at -80 °C. Aliquots were thawed at 37 °C and tested on Days 0, 1, and 5 after storage at 2-6 °C. Coagulation screening assays and activity of coagulation factors V, VIII, IX, fibrinogen, and von Willebrand factor were performed. Samples were tested for sterility on Day 5.</div></div><div><h3>Results</h3><div>One-way ANOVA revealed a significant increase in mean prothrombin time, activated partial thromboplastin time, and international normalized ratio during storage (p-value &lt; 0.001). The activity of factors V and VIII showed a significant decrease over five days (factor V - 20.0 % and factor VIII - 42.2 %; p-value &lt; 0.001), with factor VIII activity declining by 30.8 % within the first 24 hours and remaining relatively stable thereafter. Mean von Willebrand factor activity was lower in fresh frozen plasma from O blood group donors (p-value &lt; 0.05) on Days 1 and 5 of storage using an unpaired t-test. Cultures were sterile on Day 5.</div></div><div><h3>Conclusion</h3><div>Key coagulation factors were well preserved in thawed plasma till five days of storage at 2-6 °C without compromising product sterility suggesting potential for extended shelf life.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103988"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience with second allogeneic hematopoietic stem cell transplantation in Chilean patients: A single-center study","authors":"Yorman Flores,&nbsp;Javier Díaz,&nbsp;Patricio Rojas,&nbsp;José Salinas,&nbsp;Catherine Gutiérrez,&nbsp;Marcela Vidal,&nbsp;Verónica Jara,&nbsp;Elizabeth Rivera,&nbsp;María José García,&nbsp;Vicente Sandoval,&nbsp;Felipe Palacios,&nbsp;Maximiliano Vergara,&nbsp;Mauricio Ocqueteau,&nbsp;Mauricio Sarmiento","doi":"10.1016/j.htct.2025.103980","DOIUrl":"10.1016/j.htct.2025.103980","url":null,"abstract":"<div><h3>Introduction</h3><div>Allogeneic hematopoietic stem cell transplantation is potentially a curative treatment for several hematological diseases. However, post-transplant relapse remains a significant challenge. For patients who achieve a second complete remission, a second allogeneic transplantation may be a promising therapeutic option. The aim of this study was to analyze clinical outcomes including graft-versus-host disease, non-relapse mortality, and relapse rates, as well as graft sources in patients who underwent a second allogeneic transplantation in a university-based transplant program.</div></div><div><h3>Patients and Methods</h3><div>A retrospective analysis of 21 adult patients who underwent a second allogeneic transplantation between 2001 and 2023 was performed. Data on demographics, underlying disease, graft source, conditioning, graft-versus-host disease, relapse, and survival were collected. Survival estimates were calculated using the Kaplan–Meier method.</div></div><div><h3>Results</h3><div>The graft source was bone marrow in 60 % and peripheral blood in 40 % of cases. Grade III–IV acute graft-versus-host disease occurred in 5 % and extensive chronic graft-versus-host disease in 17 %. The non-relapse mortality was 69.2 %, and disease relapse occurred in 23.1 %. The one-year progression-free survival was 26.5 %, and overall survival was 42.3 %. Compared to those transplanted before 2010, patients who underwent transplantation after 2010 showed improved two-year PFS and OS, reaching 55 % and 45.4 %, respectively.</div></div><div><h3>Conclusion</h3><div>A second allogeneic transplantation may offer a survival benefit in selected patients with relapsed hematologic malignancies or bone marrow failure syndromes. Despite high non-relapse mortality, outcomes have improved in recent years with better salvage strategies.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103980"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of serum interleukin-8 with disease severity in aplastic anemia","authors":"Shahla’a Fadhil Sabir,&nbsp;Huda Ibraheem Abd AL-Lateef,&nbsp;Naam Ali Hamza","doi":"10.1016/j.htct.2025.103989","DOIUrl":"10.1016/j.htct.2025.103989","url":null,"abstract":"<div><h3>Background</h3><div>Aplastic anemia is a heterogeneous group of hematological disorders identified by the presence of one or more cytopenias in the bone marrow or the peripheral blood or both, affecting either one or multiple blood cell lineages. The pathophysiology of this disorder is unclear; however, the prevailing hypothesis posits that an aberrant immune response is responsible for the death of hematopoietic precursor stem cells due to autoreactive cytotoxic T lymphocytes in individuals with a genetic predisposition. Interleukin-8 acts as a pleiotropic prototype chemokine and serves as a powerful inhibitor of myelopoiesis and assumes an essential role in both the initiation and progression of acute inflammation and tissue damage. Consequently, it is postulated that the sustained elevation in interleukin-8 production could potentially lead to immune-mediated bone marrow failure in aplastic anemia. The aim of this study was to evaluate the serum interleukin-8 concentrations in individuals with aplastic anemia as well as investigate its potential connection with disease severity.</div></div><div><h3>Methods</h3><div>This study was performed at the National Center of Hematology and included 28 aplastic anemia patients and 30 healthy individuals matched by age and gender as a control group. The serum interleukin-8 levels were measured by the quantitative sandwich enzyme-linked immunosorbent assay (ELISA) method.</div></div><div><h3>Results</h3><div>Considerrable elevation in serum interleukin-8 levels were observed between the two groups (p-value = 0.405). Of the aplastic anemia patients, severe cases had significantly higher levels of interleukin-8 compared to non-severe patients (p-value = 0.0495), with a cutoff serum level of 7.71 pg/mL.</div></div><div><h3>Conclusion</h3><div>Interleukin-8 may have a role in the immune-mediated pathophysiology of aplastic anemia as well as have a significant correlation with disease severity.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103989"},"PeriodicalIF":1.6,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fulminant hepatitis secondary to nivolumab in a patient with Hodgkin’s Lymphoma after complete remission","authors":"Ana Júlia Negrelli dos Santos ,&nbsp;Arthur Gomes Oliveira Braga ,&nbsp;Talita Maira Bueno da Silveira","doi":"10.1016/j.htct.2025.103983","DOIUrl":"10.1016/j.htct.2025.103983","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103983"},"PeriodicalIF":1.6,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145154719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The tower of babel in hematology: The World Health Organization and International Consensus Classification systems","authors":"Daniel Mazza Matos ,&nbsp;Eduardo Magalhaes Rego","doi":"10.1016/j.htct.2025.103985","DOIUrl":"10.1016/j.htct.2025.103985","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103985"},"PeriodicalIF":1.6,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145095757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding “Challenges in diagnosing thrombotic thrombocytopenic purpura”","authors":"Cilomar Martins de Oliveira Filho,&nbsp;Brian J. Carney","doi":"10.1016/j.htct.2025.103986","DOIUrl":"10.1016/j.htct.2025.103986","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103986"},"PeriodicalIF":1.6,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145095758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in the public Chilean national health system: A single center study","authors":"Barbara Puga ,&nbsp;Francisca Bass ,&nbsp;Javiera Molina ,&nbsp;Rafael Benavente ,&nbsp;Alejandro Andrade ,&nbsp;Alejandro Majlis ,&nbsp;María Elena Cabrera ,&nbsp;Mi Kwon","doi":"10.1016/j.htct.2025.103982","DOIUrl":"10.1016/j.htct.2025.103982","url":null,"abstract":"<div><h3>Introduction</h3><div>Haploidentical peripheral stem cell transplantation with post-transplant cyclophosphamide is the most common modality in low-and-middle-income countries. This article reports the consecutive adult patients who received this modality of transplant in a single center in Chile between 2016-2021.</div></div><div><h3>Methods</h3><div>The primary outcome was overall survival. Secondary outcomes were event-free survival, II-IV acute graft-versus-host disease at Day +100, chronic graft-versus-host disease at two years and cumulative incidence of relapse.</div></div><div><h3>Results</h3><div>The median age was 25 years (Range: 15-51), and 65 % of patients were male. Ninety-four percent had a neoplastic disease (77/82), with the most common diagnosis being acute lymphoblastic leukemia (57 %). Forty-seven percent proceeded to transplant in the first complete response. Conditioning was mostly myeloablative (96 %). Primary graft failure and poor graft function were observed in 1.2 % and 13 %, respectively with five patients (6.1 %) dying before engraftment. Grade II-III acute graft-versus-host disease was seen in 29 % and chronic graft-versus-host disease was 41 % of the patients. With a median follow-up of 33 months (Range: 1-84), the estimated three-year overall survival and event-free survival were 68.3 % (95 % CI: 59–79 %) and 64.6 % (95 % CI: 55–76 %), respectively. The three-year cumulative incidence of relapse was 23 % (95 % CI: 15–33 %).</div></div><div><h3>Conclusion</h3><div>These results demonstrate encouraging survival outcomes and acceptable rates of graft-versus-host disease following haploidentical peripheral stem cell transplantation with post-transplant cyclophosphamide, suggesting its potential as a feasible option in low-resource settings.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103982"},"PeriodicalIF":1.6,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors associated with the use of red blood cells in elective cardiac surgeries: A patient blood management (PBM) view","authors":"Tainá Miotto de Souza,&nbsp;Cláudio Lucas Miranda,&nbsp;Andrezza Belluomini Castro,&nbsp;Patrícia Carvalho Garcia-Bonichini","doi":"10.1016/j.htct.2025.103987","DOIUrl":"10.1016/j.htct.2025.103987","url":null,"abstract":"<div><h3>Background</h3><div>Blood is a biological, irreplaceable, and perishable resource, provided through voluntary, altruistic, and free donation in Brazil. Although blood components are widely used in hospital settings, several challenges persist, including the limited availability of these resources, the high costs associated with their procurement, storage, and transfusion, as well as the risks inherent in the allogeneic transfusion process due to potential transfusion reactions. Therefore, there is a need to focus on Patient Blood Management (PBM) within the Brazilian transfusion system to reduce the need for transfusions, particularly of packed red blood cells, during elective cardiac surgeries.</div></div><div><h3>Objective</h3><div>To evaluate the risk factors associated with the use of packed red blood cells in elective cardiac surgeries performed at the Hospital das Clínicas, Faculty of Medicine, Botucatu.</div></div><div><h3>Methods</h3><div>This retrospective study involving 741 individuals was conducted between 2018 and 2021 with the approval of an ethics research committee. Data were analyzed using descriptive statistics, the Chi-square test, and stepwise logistic regression, with the level of significance set at 5 %.</div></div><div><h3>Results and conclusion</h3><div>Preoperative factors such as female sex (Odds ratio: 9.074; p-value &lt;0.0001), low hematocrit levels (Odds ratio: 7.498; p-value = 0.0034), and the presence of diabetes mellitus (Odds ratio: 1.779; p-value = 0.0318), as well as intraoperative factors such as extracorporeal circulation time greater than 90 min (Odds ratio: 1.68; p-value = 0.0442), were identified as risk factors for excessive bleeding and the need for packed red blood cells during surgery.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103987"},"PeriodicalIF":1.6,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VEXAS syndrome: more than just vacuoles","authors":"Marco P. Barros Pinto","doi":"10.1016/j.htct.2025.103984","DOIUrl":"10.1016/j.htct.2025.103984","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103984"},"PeriodicalIF":1.6,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall survival in multiple myeloma in Brazil: A cohort of 16 years","authors":"Deborah Marta do Santos Oliveira ,&nbsp;Isabela Cristina Menezes de Freitas ,&nbsp;Wallace Mateus Prata ,&nbsp;Isabella Zuppo Laper ,&nbsp;Pâmela Santos Azevedo ,&nbsp;Adriano de Paula Sabino ,&nbsp;Marisa Yurico Itonaga ,&nbsp;Carmino Antonio de Souza ,&nbsp;Mariângela Leal Cherchiglia ,&nbsp;Juliana Alvares Teodoro ,&nbsp;Francisco de Assis Acurcio ,&nbsp;Augusto Afonso Guerra Junior","doi":"10.1016/j.htct.2025.103962","DOIUrl":"10.1016/j.htct.2025.103962","url":null,"abstract":"<div><div>Multiple myeloma constitutes approximately 1 % of all malignancies, with a higher incidence observed in over 65-year-old individuals. New technologies have shown promising results with an increased overall survival. The objective of this cohort study was to evaluate the survival analysis of patients with multiple myeloma treated by the Brazilian Unified Health Service over 16 years and compare the effectiveness of bortezomib (Bortezomib)-based treatment with other regimens used. A retrospective national cohort study was conducted utilizing real-world evidence derived from the Brazilian Unified Health System big data. This study focused on 25,370 patients with multiple myeloma who underwent chemotherapy between 2000 and 2015. Of these patients, 50.71 % were male, and the median age was 62 years. The median overall survival was 37 months. Hematopoietic stem cell transplantation (HSCT) was the best prognostic factor with overall survival of 87 months. The bortezomib (Bortezomib)-based chemotherapy provided the best results of the different chemotherapy regimens in terms of overall survival (67 months), followed by thalidomide-based schemes with an overall survival of 54 months. Despite the significant progress made in the Brazilian health system, the National Committee for Technology Incorporation (CONITEC) needs to make quicker decisions to improve access to new oncology drugs for patients, while maintaining rigorous evaluation criteria. Earlier adoption and adequate funding for oncology services could have saved more lives compared to the treatments made available by the Unified Health Service at that time.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 4","pages":"Article 103962"},"PeriodicalIF":1.6,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}